increasing appreciation for the role of single-pill combinations for the prevention of atherosclerotic disease: A pro-polypill polemic

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 517-519

  Feldman, Ross D ^a   Nattel, Stanley ^b,c  

^a WESTERN UNIVERSITY   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DEPRESSED BLOOD PRESSURE; DRUG COMBINATION; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; MONOTHERAPY; POLYPHARMACY; PRIMARY PREVENTION; RISK REDUCTION; SINGLE PILL COMBINATION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84899641493     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.03.011     Document Type: Article

References (12)

1. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
2. Rantala A.O., Kauma H., Lilja M., et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999, 245:163-174.
3. Ogden L.G., He J., Lydick E., Whelton P.K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000, 35:539-543.
4. Cushman W.C., Ford C.E., Einhorn P.T., et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2008, 10:751-760.
5. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
6. Taylor A.A., Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003, 9:324-332.
7. Feldman R.D., Zou G.Y., Vandervoort M.K., et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009, 53:646-653.
8. Corrao G., Nicotra F., Parodi A., et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011, 58:566-572.
9. Jaffe M.G., Lee G.A., Young J.D., Sidney S., Go A.S. Improved blood pressure control associated with a large-scale hypertension program. JAMA 2013, 310:699-705.
10. Spence J.D. A single fixed-dose combination for all patients is bad medicine. Can J Cardiol 2014, 30:513-516.
11. Thom S., Poulter N., Field J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013, 310:918-929.
12. Castellano J.M., Sanz G., Fuster V. Evolution of the polypill concept and ongoing clinical trials. Can J Cardiol 2014, 30:520-526.